Year: 2022

221208153815_ibisPaintSS_28229

Hoping to lessen the despair caused by the China’s lockdown, ibis inc. (Japan) is offering the illustration app, which is one of most downloaded worldwide, free of charge for a limited time

ORUM2BLOGO2B-2BPNG

Orum Therapeutics Presents Positive Preclinical Data of ORM-6151, a First-in-Class, CD33-GSPT1 Dual-Precision Targeted Protein Degrader for AML, at ASH 2022

BOSTON & DAEJEON, South Korea--(BUSINESS WIRE)--#ADC--Orum Therapeutics, a private biotechnology company pioneering the development of tumor-directed targeted protein degraders (TPDs),...